celecoxib has been researched along with Carcinoma, Transitional Cell in 11 studies
Carcinoma, Transitional Cell: A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In these studies, we evaluated the COX-2 inhibitor celecoxib in two rodent models of urinary bladder cancer." | 7.70 | Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. ( Grubbs, CJ; Hill, DL; Kelloff, GJ; Koki, AT; Leahy, KM; Lubet, RA; Masferrer, JL; Seibert, K; Steele, VE, 2000) |
| "Celecoxib was not shown to reduce the risk of recurrence in intermediate- or high-risk non-muscle-invasive bladder cancer (NMIBC), although celecoxib was associated with delayed time to recurrence in pT1 NMIBC patients." | 5.30 | BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). ( Andrews, S; Blazeby, J; Bogle, R; Brough, R; Burnett, S; Cresswell, J; Cruickshank, C; Hall, E; Huddart, R; Johnson, M; Kelly, JD; Madaan, S; Maynard, L; Mostafid, H; Palmer, A; Porta, N; Protheroe, A; Tan, WS, 2019) |
| " We hypothesised that a combination of the cyclooxygenase 2 (COX-2) selective inhibitor celecoxib and intravesical bacillus Calmette-Guérin (BCG), an effective tumour immunoprophylaxis and ablative therapy for non-muscle-invasive bladder cancer, would be more effective than BCG alone." | 3.74 | Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma. ( Davies, BR; Dovedi, SJ; Kelly, JD; Kirby, JA; Leung, H, 2008) |
| " In these studies, we evaluated the COX-2 inhibitor celecoxib in two rodent models of urinary bladder cancer." | 3.70 | Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. ( Grubbs, CJ; Hill, DL; Kelloff, GJ; Koki, AT; Leahy, KM; Lubet, RA; Masferrer, JL; Seibert, K; Steele, VE, 2000) |
| "Celecoxib was also administered via the diet to allow for systemic delivery of the drug." | 1.37 | Preclinical evaluation of a gene therapy treatment for transitional cell carcinoma. ( Godbey, WT; Zhang, X, 2011) |
| "The human bladder cancer cell lines UM-UC-1, -3, and -6 were assayed for COX-2 expression by Western analysis using a monoclonal antibody to COX-2." | 1.33 | Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer. ( Fischer, SM; Gee, J; Grossman, HB; Jendiroba, D; Lee, IL; Sabichi, AL, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kelly, JD | 2 |
| Tan, WS | 1 |
| Porta, N | 1 |
| Mostafid, H | 1 |
| Huddart, R | 1 |
| Protheroe, A | 1 |
| Bogle, R | 1 |
| Blazeby, J | 1 |
| Palmer, A | 1 |
| Cresswell, J | 1 |
| Johnson, M | 1 |
| Brough, R | 1 |
| Madaan, S | 1 |
| Andrews, S | 1 |
| Cruickshank, C | 1 |
| Burnett, S | 1 |
| Maynard, L | 1 |
| Hall, E | 1 |
| Gore, JL | 1 |
| Wright, JL | 1 |
| Goldstein, MR | 1 |
| Mascitelli, L | 1 |
| Huang, KH | 1 |
| Kuo, KL | 1 |
| Ho, IL | 1 |
| Chang, HC | 1 |
| Chuang, YT | 1 |
| Lin, WC | 1 |
| Lee, PY | 1 |
| Chang, SC | 1 |
| Chiang, CK | 1 |
| Pu, YS | 1 |
| Chou, CT | 1 |
| Hsu, CH | 1 |
| Liu, SH | 1 |
| Dhawan, D | 2 |
| Craig, BA | 1 |
| Cheng, L | 1 |
| Snyder, PW | 1 |
| Mohammed, SI | 1 |
| Stewart, JC | 2 |
| Zheng, R | 2 |
| Loman, RA | 1 |
| Foster, RS | 1 |
| Knapp, DW | 2 |
| Zhang, X | 1 |
| Godbey, WT | 1 |
| Gee, J | 1 |
| Lee, IL | 1 |
| Jendiroba, D | 1 |
| Fischer, SM | 1 |
| Grossman, HB | 1 |
| Sabichi, AL | 1 |
| Dovedi, SJ | 1 |
| Kirby, JA | 1 |
| Davies, BR | 1 |
| Leung, H | 1 |
| Brandau, S | 1 |
| Jeffreys, AB | 1 |
| Grubbs, CJ | 1 |
| Lubet, RA | 1 |
| Koki, AT | 1 |
| Leahy, KM | 1 |
| Masferrer, JL | 1 |
| Steele, VE | 1 |
| Kelloff, GJ | 1 |
| Hill, DL | 1 |
| Seibert, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614] | Phase 2 | 58 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for celecoxib and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004).
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherap | 2019 |
Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 2010 |
9 other studies available for celecoxib and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Can We Prevent Bladder Cancer Recurrences?
Topics: Carcinoma, Transitional Cell; Celecoxib; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplas | 2019 |
Re: John L. Gore, Jonathan L. Wright. Can We Prevent Bladder Cancer Recurrences? Eur Urol 2019;75:602-3.
Topics: Carcinoma, Transitional Cell; Celecoxib; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplas | 2019 |
Celecoxib-induced cytotoxic effect is potentiated by inhibition of autophagy in human urothelial carcinoma cells.
Topics: Adenine; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 7; Carcinoma, Transitional Cell | 2013 |
Preclinical evaluation of a gene therapy treatment for transitional cell carcinoma.
Topics: Animals; BCG Vaccine; Carcinoma, Transitional Cell; Caspase 3; Caspase 9; Celecoxib; Cell Line, Tumo | 2011 |
Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer.
Topics: Apoptosis; Blotting, Western; Carcinoma, Transitional Cell; Celecoxib; Cell Line, Tumor; Cell Prolif | 2006 |
Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma.
Topics: Analysis of Variance; Animals; BCG Vaccine; Blotting, Western; Carcinoma, Transitional Cell; Celecox | 2008 |
Editorial comment on: celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma.
Topics: Animals; BCG Vaccine; Carcinoma, Transitional Cell; Celecoxib; Cyclooxygenase Inhibitors; Dinoprosto | 2008 |
Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Transitional Cell; Celecoxib; Cell Line, Tumor; Cell Prolif | 2008 |
Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats.
Topics: Animals; Anticarcinogenic Agents; Butylhydroxybutylnitrosamine; Carcinogens; Carcinoma, Squamous Cel | 2000 |